Last reviewed · How we verify
F-18-PSMA-1007
F-18-PSMA-1007 is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors.
F-18-PSMA-1007 is a fluorine-18 labeled small molecule that binds to prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of PSMA-expressing tumors. Used for PET imaging of PSMA-positive lesions in prostate cancer patients, Detection and staging of metastatic prostate cancer.
At a glance
| Generic name | F-18-PSMA-1007 |
|---|---|
| Sponsor | ABX advanced biochemical compounds GmbH |
| Drug class | Radiopharmaceutical; PSMA-targeting PET imaging agent |
| Target | PSMA (prostate-specific membrane antigen) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
F-18-PSMA-1007 is a radiopharmaceutical tracer that targets PSMA, a transmembrane protein highly expressed on prostate cancer cells and certain other malignancies. The fluorine-18 radiolabel enables PET imaging to visualize and localize PSMA-positive lesions, facilitating tumor detection, staging, and treatment monitoring. This imaging agent helps clinicians identify metastatic disease and guide therapeutic decisions in PSMA-targeted treatment strategies.
Approved indications
- PET imaging of PSMA-positive lesions in prostate cancer patients
- Detection and staging of metastatic prostate cancer
Common side effects
- Radiation exposure (inherent to PET imaging)
- Injection site reactions
Key clinical trials
- PSMA PET for Treatment Response evaLuation of systemIC Therapies in prostAte caNcer (PELICAN)
- The Role of 18F-PSMA PET in Prostate Cancer Diagnosis in Equivocal MRI (NA)
- Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer (PHASE3)
- Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC (PHASE1, PHASE2)
- GUidance In Prostate Cancer DEtection With 18F-PSMA-1007-PET/MRI and Targeted Biopsies (NA)
- 18F-PSMA-1007 PET/CT in Prostate Cancer - Access Trial 2022 to 2028 (PHASE3)
- Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer (PHASE3)
- Evaluation of the 18F-PSMA Positron Emission Tomography (PET)/CT in Patients With Medullary Thyroid Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F-18-PSMA-1007 CI brief — competitive landscape report
- F-18-PSMA-1007 updates RSS · CI watch RSS
- ABX advanced biochemical compounds GmbH portfolio CI